![Edgar Braendle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Edgar Braendle
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2024
Karriereverlauf von Edgar Braendle
Ehemalige bekannte Positionen von Edgar Braendle
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AUTOLUS THERAPEUTICS PLC | Corporate Officer/Principal | 15.07.2021 | 14.03.2024 |
Arup Laboratories, Inc.
![]() Arup Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Arup Laboratories, Inc. provides clinical and anatomic pathology laboratory services. It offers testing services in the areas of anatomic pathology, pain management, genetics, pediatrics, infectious disease, oncology, and other specialties. The company is headquartered in Salt Lake City, UT. | Vorstandsvorsitzender | 01.08.2016 | 11.08.2017 |
Präsident | 01.08.2016 | 11.08.2017 | |
Boston Biomedical, Inc.
![]() Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Sumitomo Dainippon Pharma Oncology, Inc.
![]() Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Edgar Braendle
RWTH Aachen University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Vereinigtes Königreich | 2 |
Deutschland | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Chief Executive Officer | 1 |
President | 1 |
Sektoral
Commercial Services | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AUTOLUS THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 3 |
---|---|
Arup Laboratories, Inc.
![]() Arup Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Arup Laboratories, Inc. provides clinical and anatomic pathology laboratory services. It offers testing services in the areas of anatomic pathology, pain management, genetics, pediatrics, infectious disease, oncology, and other specialties. The company is headquartered in Salt Lake City, UT. | Commercial Services |
Sumitomo Dainippon Pharma Oncology, Inc.
![]() Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
Boston Biomedical, Inc.
![]() Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
- Börse
- Insiders
- Edgar Braendle
- Erfahrung